GlassScriptPhysician profile
Phaik Mae Obermeyer
NPI 1831163682
$5,652.53
in general payments reported to CMS, 2019-2025
50 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $635 · 2021: $768 · 2022: $807 · 2023: $874 · 2024: $823 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $717.11 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $638.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $473.89 | 2019-2025 | Breztri, Farxiga, Bevespi Aerosphere |
| Novo Nordisk INC | $385.61 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Mylan Specialty L.P. | $361.34 | 2019-2024 | Yupelri |
| Abbvie INC. | $319.24 | 2021-2025 | |
| Pfizer INC. | $243.59 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $234.80 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.67 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $167.31 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $131.20 | 2019-2025 | Zoryve |
| Currax Pharmaceuticals LLC | $119.30 | 2019-2021 | |
| Esperion Therapeutics, INC. | $116.09 | 2021-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.15 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $98.12 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phaik Obermeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.